|Articles|September 25, 2016

Tufts CSDD Releases Findings from Diabetes Study

September 26, 2016

According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.

Read the full release here

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content